Entrada Therapeutics Announces Clinical Candidate, ENTR-601-45, for the Potential Treatment of People Living with Duchenne Muscular Dystrophy who are Exon 45 Skipping Amenable
January 09, 2023 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Jan. 09, 2023 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Announces Clinical Hold on IND Application for ENTR-601-44 in Duchenne Muscular Dystrophy
December 19, 2022 16:30 ET
|
Entrada Therapeutics, Inc.
BOSTON, Dec. 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Present at Evercore ISI 5th Annual HealthCONx Virtual Conference
November 22, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Nov. 22, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biotechnology company aiming to transform the lives of patients and become the world’s foremost intracellular...
Entrada Therapeutics Reports Third Quarter 2022 Financial Results
November 07, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 for the potential treatment of patients with Duchenne muscular dystrophy who are exon...
Entrada Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference
August 30, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, Aug. 30, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics Reports Second Quarter 2022 Financial Results
August 11, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
On track to submit Investigational New Drug application to the U.S. Food and Drug Administration for ENTR-601-44 targeting Duchenne muscular dystrophy in Q4 2022 Cash runway into 2H 2024 with $244...
Entrada Therapeutics Announces Collaboration with the Myotonic Dystrophy Clinical Research Network to Study the Natural History of Myotonic Dystrophy Type 1
August 04, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
The natural history study will generate data to further the ongoing efforts of the myotonic dystrophy research community to understand disease progression and identify potential clinical outcome...
Entrada Therapeutics Appoints Karla MacDonald as Chief Corporate Affairs Officer
July 19, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, July 19, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Present at William Blair Biotech Focus Conference
July 06, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, July 06, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...
Entrada Therapeutics to Present at Goldman Sachs Global Healthcare Conference
June 01, 2022 07:00 ET
|
Entrada Therapeutics, Inc.
BOSTON, June 01, 2022 (GLOBE NEWSWIRE) -- Entrada Therapeutics, Inc. (Nasdaq: TRDA), a biopharmaceutical company aiming to transform the lives of patients by establishing intracellular Endosomal...